

Tamás Masszi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6720513/publications.pdf>

Version: 2024-02-01

122
papers

10,799
citations

81900

39
h-index

31849

101
g-index

130
all docs

130
docs citations

130
times ranked

9661
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2023, 108, 890-897.	3.5	65
2	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314.	1.3	8
3	Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality. <i>Thrombosis and Haemostasis</i> , 2022, 122, 240-256.	3.4	15
4	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	4.6	32
5	Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement. <i>Biomedicines</i> , 2022, 10, 519.	3.2	1
6	Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers. <i>Pathology and Oncology Research</i> , 2022, 28, 1610276.	1.9	9
7	Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients. <i>Biomarkers in Medicine</i> , 2022, 16, 317-330.	1.4	13
8	Serum fetuin-A level is independent of Helicobacter pylori postinfection status in systemic lupus erythematosus. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2022, , .	0.8	0
9	Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 796109.	2.6	5
10	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. <i>British Journal of Haematology</i> , 2021, 193, 561-569.	2.5	10
11	Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 663187.	4.8	87
12	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. <i>Leukemia</i> , 2021, 35, 1344-1355.	7.2	43
13	Beneficial Effect of Lenalidomide-Dexamethasone Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers. <i>Pathology and Oncology Research</i> , 2021, 27, 613264.	1.9	2
14	Screening and monitoring of the BTK ^{C481S} mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. <i>British Journal of Haematology</i> , 2021, 194, 355-364.	2.5	13
15	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2361-2371.	13.7	177
16	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate- or high-risk myelofibrosis. <i>British Journal of Haematology</i> , 2021, 195, 244-248.	2.5	37
17	Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features. <i>Genes</i> , 2021, 12, 1152.	2.4	4
18	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	1.6	53

#	ARTICLE	IF	CITATIONS
19	Investigation of TGFBI \sim 1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 215-223.	2.4	1
20	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
21	Identification of the best-suited donor for generating virus-specific T cells. <i>Vox Sanguinis</i> , 2020, 115, 18-26.	1.5	2
22	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e28-e39.	4.6	94
23	Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma. <i>Genes</i> , 2020, 11, 785.	2.4	18
24	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	17.0	32
25	Usefulness of a Novel Electrocardiographic Score to Estimate the Pre-Test Probability of Acute Pulmonary Embolism. <i>American Journal of Cardiology</i> , 2020, 130, 143-151.	1.6	5
26	$\text{c}\mu\text{MYC}$ expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide+dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	2.2	8
27	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e226-e237.	4.6	93
28	Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (\geq 65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom. <i>Blood</i> , 2020, 136, 7-8.	1.4	3
29	Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers. <i>Blood</i> , 2020, 136, 32-33.	1.4	1
30	Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. <i>International Journal of Hematology</i> , 2019, 110, 559-565.	1.6	25
31	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33
32	Coexistence of aortic valve stenosis and cardiac amyloidosis: echocardiographic and clinical significance. <i>Cardiovascular Ultrasound</i> , 2019, 17, 32.	1.6	12
33	Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms. <i>Pathology</i> , 2019, 51, 301-307.	0.6	7
34	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 945-954.	2.5	124
35	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2018, 96, 73-81.	2.8	40
36	Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2018, 124, 2523-2533.	4.1	18

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. <i>Annals of Hematology</i> , 2018, 97, 617-627.	1.8	23
38	Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. <i>Leukemia Research</i> , 2018, 65, 42-48.	0.8	19
39	Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study). <i>Pathology and Oncology Research</i> , 2018, 24, 199-205.	1.9	5
40	The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 710-716.	1.3	1
41	High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation lymphoma working party. <i>American Journal of Hematology</i> , 2018, 93, 40-46.	4.1	19
42	Sex-specific survival difference in association with HLA-DRB1*04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies. <i>Human Immunology</i> , 2018, 79, 13-19.	2.4	1
43	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. <i>British Journal of Haematology</i> , 2018, 182, 279-284.	2.5	3
44	Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. <i>Blood</i> , 2018, 132, 2639-2642.	1.4	172
45	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
46	Skin-homing CD8 ⁺ T cells preferentially express GPIIb/IIIa-anchored peptidase inhibitor 16, an inhibitor of cathepsin K. <i>European Journal of Immunology</i> , 2018, 48, 1944-1957.	2.9	16
47	Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature. <i>Journal of Oncology</i> , 2018, 2018, 1-7.	1.3	32
48	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.4	61
49	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-enalidomide-dexamethasone versus placebo-enalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	4.1	41
50	Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV). <i>Blood</i> , 2018, 132, 1753-1753.	1.4	7
51	Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE). <i>Journal of Clinical Oncology</i> , 2018, 36, e20024-e20024.	1.6	2
52	Description of the First Cases with ADAMTS13 Mutations in Hungary. <i>Blood</i> , 2018, 132, 5003-5003.	1.4	0
53	Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers. <i>Blood</i> , 2018, 132, 3257-3257.	1.4	1
54	Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 391-398.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	2.5	58
56	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.5	45
57	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	1.4	90
58	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	3.5	48
59	Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 734-742.	0.4	8
60	Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. <i>Pathology and Oncology Research</i> , 2017, 23, 165-171.	1.9	5
61	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	3.5	140
62	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861
63	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
64	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
65	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 860-867.	2.5	30
66	Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. <i>European Journal of Haematology</i> , 2016, 97, 192-200.	2.2	46
67	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	27.0	1,246
68	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	10.7	723
69	Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 98-104.	2.5	21
70	Comparable Results of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Complete Molecular Remission: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 512-512.	1.4	0
71	The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 666-666.	1.4	0
72	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. <i>British Journal of Haematology</i> , 2015, 171, 344-354.	2.5	26

#	ARTICLE	IF	CITATIONS
73	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	1.6	394
74	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. <i>New England Journal of Medicine</i> , 2015, 372, 426-435.	27.0	720
75	Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2015, 56, 120-127.	1.3	28
76	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1853-1862.	13.7	633
77	Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 1252-1257.	1.6	57
78	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. <i>JAMA Oncology</i> , 2015, 1, 643.	7.1	362
79	<i><i><sc>NFKB</sc>1</i> <i>âˆ™</i> <i><i>94ins/del<sc>ATTG</sc></i> polymorphism is a novel prognostic marker in first lineâ€treated multiple myeloma. <i>British Journal of Haematology</i> , 2015, 168, 679-688.	2.5	10
80	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	27.0	1,144
81	A phase 2, randomized, doubleâ€blind, placeboâ€controlled study of siltuximab (antiâ€ILâ€6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 42-49.	4.1	116
82	Medium-sized <i><i>FLT3</i></i> internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. <i>Leukemia and Lymphoma</i> , 2014, 55, 1510-1517.	1.3	18
83	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24â€month followâ€up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	4.1	102
84	Peripheral Blood Stem Cell Mobilization and Engraftment after Autologous Stem Cell Transplantation with Biosimilar rhG-CSF. <i>Advances in Therapy</i> , 2014, 31, 451-460.	2.9	21
85	Diffusion weighted magnetic resonance imaging demonstrates tumor response following palliative embolization of a recurrent shoulder plasmacytoma. <i>World Journal of Surgical Oncology</i> , 2014, 12, 271.	1.9	0
86	Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. <i>Haematologica</i> , 2014, 99, 1184-1190.	3.5	83
87	Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial. <i>Blood</i> , 2014, 124, 3181-3181.	1.4	1
88	Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results. <i>Blood</i> , 2014, 124, 709-709.	1.4	0
89	Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimenâ€”A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 3549-3556.	1.6	143
90	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 247-255.	1.6	69

#	ARTICLE	IF	CITATIONS
91	Quality of life and its socio-demographic and psychological determinants after bone marrow transplantation. <i>European Journal of Haematology</i> , 2013, 91, 135-140.	2.2	15
92	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1028-1035.	1.3	30
93	Analyses of Donor-Derived Keratinocytes in Hairy and Nonhairy Skin Biopsies of Female Patients Following Allogeneic Male Bone Marrow Transplantation. <i>Stem Cells and Development</i> , 2012, 21, 152-157.	2.1	7
94	Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. <i>Leukemia and Lymphoma</i> , 2012, 53, 907-914.	1.3	30
95	Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients. <i>Acta Haematologica</i> , 2012, 127, 34-42.	1.4	27
96	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2475-2482.	1.6	185
97	Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia. <i>Medical Oncology</i> , 2012, 29, 2136-2142.	2.5	8
98	Characterization and Function of Histamine Receptors in Human Bone Marrow Stromal Cells. <i>Stem Cells</i> , 2012, 30, 222-231.	3.2	28
99	Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 438-442.	0.8	48
100	Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. <i>European Journal of Haematology</i> , 2011, 86, 488-495.	2.2	34
101	Radioguided lymph node biopsy of a chemoresistant lymph node detected on interim FDG PET-CT in Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2011, 93, 545-550.	1.6	6
102	Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. <i>American Journal of Hematology</i> , 2011, 86, 550-553.	4.1	20
103	Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. <i>Leukemia and Lymphoma</i> , 2011, 52, 1711-1719.	1.3	22
104	Lymphoid aggregates may contribute to the migration and epithelial commitment of bone marrow-derived cells in colonic mucosa. <i>Journal of Clinical Pathology</i> , 2011, 64, 771-775.	2.0	8
105	Secondary ALK Negative Anaplastic Large Cell Lymphoma in a Patient With Lymphomatoid Papulosis of 40 Years Duration. <i>American Journal of Dermatopathology</i> , 2010, 32, 708-712.	0.6	6
106	Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. <i>Experimental Hematology</i> , 2010, 38, 1219-1230.	0.4	10
107	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study. <i>Cancer</i> , 2010, 116, 3852-3861.	4.1	115
108	Retrospective Survey on the Prevalence and Outcome of Prior Autoimmune Diseases in Patients with Aplastic Anemia Reported to the Registry of the European Group for Blood and Marrow Transplantation. <i>Acta Haematologica</i> , 2010, 124, 19-22.	1.4	5

#	ARTICLE	IF	CITATIONS
109	Serum β_2 -microglobulin measured by immunonephelometry: expression patterns and reference intervals in healthy adults. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 585-9.	2.3	16
110	<i>HFE</i> C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 929-934.	2.5	11
111	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093.	1.6	154
112	Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. <i>Annals of Hematology</i> , 2009, 88, 1005-1013.	1.8	20
113	Familial multiple myeloma. Two more families. <i>Open Medicine (Poland)</i> , 2009, 4, 501-505.	1.3	1
114	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. <i>Blood</i> , 2009, 114, 1166-1173.	1.4	129
115	Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. <i>Heart Failure Reviews</i> , 2008, 13, 227-244.	3.9	12
116	Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2008, 93, 1203-1210.	3.5	158
117	Analysis of platelet β_2 -adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. <i>Thrombosis and Haemostasis</i> , 2008, 100, 829-838.	3.4	31
118	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. <i>Blood</i> , 2007, 109, 5143-5150.	1.4	356
119	Persistent long-term human herpesvirus 6 (HHV-6) infection in a patient with langerhans cell histiocytosis. <i>Pathology and Oncology Research</i> , 2007, 13, 157-160.	1.9	19
120	Ten-Year Remission of Psoriasis after Allogeneic but Not Autologous Bone Marrow Transplantation. <i>Dermatology</i> , 2006, 212, 88-89.	2.1	11
121	Apoptosis Induction by Retinoids in Eosinophilic Leukemia Cells: Implication of Retinoic Acid Receptor- β Signaling in All-Trans-Retinoic Acid Hypersensitivity. <i>Cancer Research</i> , 2006, 66, 6336-6344.	0.9	18
122	Remarkably Reduced Transplant-Related Complications by Dibromomannitol Non-Myeloablative Conditioning before Allogeneic Bone Marrow Transplantation in Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2001, 105, 64-70.	1.4	14